Rhabdomyolysis with Acute Renal Failure and Deep Vein Thrombosis Induced by Antipsychotic Drugs: A Case Report

Abstract

Atypical antipsychotics, the first line therapy for schizophrenia, have already been reported as causing rhabdomyolysis or isolated elevation in serum creatine kinase (SCK). This case report dealing with rhabdomyolysis in a 25-year-old man treated with antipsychotics is particularly unusual, due to the extremely high elevation in SCK and the ensuing acute renal failure. He was treated with loxapine 400 mg/day and risperidone 4 mg/day for 4 days and then loxapine was replaced by levomepromazine 300 mg/day. A series of laboratory examinations showed: SCK 43 650 UI/L, creatinine 392 µmol/L. An acute renal failure (acute tubular necrosis) after iatrogenic rhabdomyolysis was diagnosed, requiring hemodialysis. Furthermore, the patient also developed a deep vein thrombosis (DVT) attributed to his antipsychotic treatment. This case underlines the importance of taking rhabdomyolysis and DVT risk factors into account in patients treated with antipsychotics. Indeed, in this case we note that rhabdomyolysis was probably promoted by the interruption and the reintroduction of the treatment more than by possible dehydration, because no other risk factor could be identified.

Key words

rhabdomyolysis - kidney failure - thrombosis - serum creatine kinase (SCK) - antipsychotic drugs

^* These authors contributed equally to this work

• References

• 1 Devarajan S, Dursun SM. Antipsychotic drugs, serum creatine kinase (CPK) and possible mechanisms. Psychopharmacology (Berl) 2000; 152: 122
• 2 Meltzer HY, Cola PA, Parsa M et al. Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 1996; 15: 395-405
• 3 Masopust J, Malý R, Vališ M et al. Risk of venous thromboembolism during treatment with antipsychotic agents. Psychiatry Clin Neurosci 2012; 66: 541-552
• 4 Sheikhmoonesi F, Bahari Saravi SF. Deep venous thrombosis and atypical antipsychotics: three cases report. Daru J Fac Pharm Tehran Univ Med Sci 2012; 20: 71
• 5 Boulicot V, Merlot A, Sebeyran A et al. Rhabdomyolysis with antipsychotic drug treatment: a case report. Thérapie 2012; 67: 484-487
• 6 Allenet B, Schmidlin S, Genty C et al. Antipsychotic drugs and risk of pulmonary embolism. Pharmacoepidemiol Drug Saf 2012; 21: 42-48
• 7 Hägg S, Spigset O, Söderström TG et al. Association of venous thromboembolism and clozapine. Lancet 2000; 355: 1155-1156
• 8 Koga M, Nakayama K. Body weight gain induced by a newer antipsychotic agent reversed as negative symptoms improved. Acta Psychiatr Scand 2005; 112: 75-76 discussion 77
• 9 Metzer WS, Canoso RT, Newton JE et al. Anticardiolipin antibodies in a sample of chronic schizophrenics receiving neuroleptic therapy. South Med J 1994; 87: 190-192
• 10 Davis S, Kern HB, Asokan R et al. Antiphospholipid antibodies associated with clozapine treatment. Am J Hematol 1994; 46: 166-167
• 11 Shen H, Li R, Xiao H et al. Higher serum clozapine level is associated with increased antiphospholipid antibodies in schizophrenia patients. J Psychiatr Res 2009; 43: 615-619
• 12 McCall WV, Mann SC, Shelp FE et al. Fatal pulmonary embolism in the catatonic syndrome: two case reports and a literature review. J Clin Psychiatry 1995; 56: 21-25
• 13 Parker C, Coupland C, Hippisley-Cox J et al. Antipsychotic drugs and risk of venous thromboembolism: nested case-control study. BMJ 2010; 341: c4245
• 14 Jönsson AK, Horváth-Puhó E, Hägg S et al. Antipsychotics and risk of venous thromboembolism: A population-based case-control study. Clin Epidemiol 2009; 1: 19-26
• 15 Kamijo Y, Soma K, Nagai T et al. Acute massive pulmonary thromboembolism associated with risperidone and conventional phenothiazines. Circ J Off J Jpn Circ Soc 2003; 67: 46-48